Style | Citing Format |
---|---|
MLA | Maleki F, et al.. "Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment." Life Sciences, vol. 304, no. , 2022, pp. -. |
APA | Maleki F, Salimi M, Shirkoohi R, Rezaei M (2022). Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment. Life Sciences, 304(), -. |
Chicago | Maleki F, Salimi M, Shirkoohi R, Rezaei M. "Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment." Life Sciences 304, no. (2022): -. |
Harvard | Maleki F et al. (2022) 'Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment', Life Sciences, 304(), pp. -. |
Vancouver | Maleki F, Salimi M, Shirkoohi R, Rezaei M. Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment. Life Sciences. 2022;304():-. |
BibTex | @article{ author = {Maleki F and Salimi M and Shirkoohi R and Rezaei M}, title = {Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment}, journal = {Life Sciences}, volume = {304}, number = {}, pages = {-}, year = {2022} } |
RIS | TY - JOUR AU - Maleki F AU - Salimi M AU - Shirkoohi R AU - Rezaei M TI - Mitotherapy in Doxorubicin Induced Cardiotoxicity: A Promising Strategy to Reduce the Complications of Treatment JO - Life Sciences VL - 304 IS - SP - EP - PY - 2022 ER - |